Disclosed herein is a compound of formula I wherein the variables are defined in the specification and the use thereof in the treatment of a condition associated with aberrant levels of CGRP, specifically wherein the condition is migraine. Preferable embodiments of the invention include: (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin -9-y 1 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate 5-(2,3-difluorophenyl)-2-oxocycloheptyl 4-(2-oxo-2,3 -dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (6,9-trans)-2-cyano-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yI 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate and N-((6R,9R)-3 -amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide.
